Diallo-Danebrock, Raihanatou and Ting, Evelyn and Gluz, Oleg and Herr, Alexander and Mohrmann, Svjetlana and Geddert, Helene and Rody, Achim and Schaefer, Karl-Ludwig and Baldus, Stephan E. and Hartmann, Arndt and Wild, Peter J. and Burson, Michael and Gabbert, Helmut E. and Nitz, Ulrike and Poremba, Christopher (2007) Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy. CLINICAL CANCER RESEARCH, 13 (2). pp. 488-497. ISSN 1078-0432,
Full text not available from this repository. (Request a copy)Abstract
Purpose: To characterize the prognostic and predictive impact of protein expression profiles in high-risk breast cancer patients who had previously been shown to benefit from high-dose chemotherapy (HDCT) in comparison to dose-dense chemotherapy (DDCT). Experimental Design: The expression of 34 protein markers was evaluated using tissue microarrays containing paraffin-embedded breast cancer samples from 236 patients who were randomized to the West German Study Group AM01 trial. Results: (a) 24 protein markers of the initial panel of 34 markers were sufficient to identify five profile clusters (subtypes) by K-means clustering: luminal-A (27%), luminal-B (12%), HER-2 (21%), basal-like (13%) cluster, and a so-called "multiple marker negative" (MMN) cluster (27%) characterized by the absence of specifying markers. (b) After DDCT HER-2 and basal-like groups had significantly worse event-free survival [EFS; hazard ratio (HR), 3.6 [95% confidence interval (95% CI), 1.65-8.18; P = 0.0011 and HR, 3.7 (95% Cl, 1.68-8.48; P < 0.0001), respectively] when compared with both luminal groups. (c) After HDCT the HR was 1.5 (95% Cl, 0.76-3.05) for EFS in the HER-2 subgroup and 1.1 (95% Cl, 0.37-3.32) in the basal-like subgroup, which indicates a better outcome for patients in the HER-2 and basal-like subgroups who received HDCT The MMN cluster showed a trend to a better EFS after HDCT compared with DDCT Conclusions: Protein expression profiling in high-risk breast cancers identified five subtypes, which differed with respect to survival and response to chemotherapy: In contrast to luminal-A and luminal-B subtypes, HER-2 and basal-like subgroups had a significant predictive benefit, and the MMN cluster had a trend to a predictive benefit, both from HDCT when compared with DDCT.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | TISSUE MICROARRAY ANALYSIS; TERM-FOLLOW-UP; PROGNOSTIC-SIGNIFICANCE; MULTIVARIATE-ANALYSIS; MOLECULAR SUBTYPES; DUCTAL CARCINOMA; TUMOR SUBTYPES; IN-SITU; SURVIVAL; CLASSIFICATION; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Pathologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 23 Dec 2020 07:46 |
| Last Modified: | 23 Dec 2020 07:46 |
| URI: | https://pred.uni-regensburg.de/id/eprint/33293 |
Actions (login required)
 |
View Item |
